Interferon-alpha and its effects on post-transplant lymphoproliferative disorders

Area of Science:

• Immunology
• Virology
• Oncology

Background:

• Epstein-Barr virus (EBV) transformation of B lymphocytes drives high IL-10 secretion and promotes a Th2 immune environment.
• EBV's BCRF1 gene product mimics human IL-10, potentially initiating a cascade that suppresses Th1 activity.
• Elevated IL-4, IL-10, and IgE in PTLD patients suggest an immunoregulatory imbalance, with Th1 suppression and/or Th2 up-regulation.

Purpose of the Study:

• To investigate the potential of Interferon-alpha (IFN-alpha) in treating EBV-associated post-transplant lymphoproliferative disorder (PTLD).
• To evaluate the efficacy of IFN-alpha in patients with PTLD who do not respond to reduced immunosuppression.
• To compare the outcomes of IFN-alpha therapy with existing PTLD treatment mortality rates.

Main Methods:

• Review of existing literature on IFN-alpha treatment for PTLD and EBV-related lymphoproliferative disorders (BLPD).
• Analysis of reported cases of PTLD and BLPD treated with IFN-alpha, including patient outcomes and mortality.
• Comparison of mortality rates in IFN-alpha treated patients versus historical controls for PTLD.

Main Results:

• In vitro studies demonstrate IFN-alpha's effectiveness against EBV.
• Limited in vivo data from 21 reported cases of BLPD treated with IFN-alpha showed a 14% mortality rate (3/21).
• IFN-alpha therapy resulted in complete remission in 15 patients, improvement in 4, and death in 2, comparing favorably to PTLD mortality rates of 23-81%.

Conclusions:

• IFN-alpha exhibits promising efficacy in treating EBV-positive PTLD, particularly in patients unresponsive to immunosuppression reduction.
• The observed mortality rate with IFN-alpha is significantly lower than that of untreated or conventionally treated PTLD.
• A large, multi-centered prospective trial is warranted to compare IFN-alpha (with or without IVIg) against other PTLD treatment options.